Chairman of Greater China
John Wong is a core member of Boston Consulting Group’s Health Care practice and the chairman of the firm’s Greater China system. He previously served as the chairman of the Asia-Pacific region and on BCG’s Global Executive and Operating committees. He was named a Top 25 Consultant by Consulting magazine in 2004.
John is an expert in the biopharmaceutical and medtech sectors and serves both global pharmaceutical and medtech companies in Asia, as well as local biopharmaceutical companies in China
Before joining BCG in 1982, John worked in R&D for Milliken Research. He specialized in modeling the non-Newtonian fluid mechanics of chemicals systems.
Multinational companies need to map a strategy to tap into China’s growth—and compete with increasingly innovative “homegrown” Chinese biopharma companies.
In crisis lies opportunity. While most hospitals are struggling to weather this crisis, the likely winners are already acting to succeed in a post-COVID-19 world.
Despite rising costs and trade disputes, the country’s manufacturing sector is poised for strong growth.
Global challengers are providing exciting new models for others to follow.
Even the most powerful traditional competitors need to develop digital strategies and capabilities.
Digital capabilities put many global challengers in a strong position to challenge developed-market companies for leadership.
The economic future in emerging markets looks increasingly digital.
Dissatisfaction with the public health care system is prompting many Chinese to consider alternatives. One answer is reimbursement insurance, likely to be a $60 billion market by 2020.
Digital technology is transforming health care in China, and players including pharmaceutical and medtech companies, distributors and retailers, and payers will need to adapt.
Health care reform in China will transform the medtech market in the years ahead, forcing both multinational corporations and local companies to adapt.
Powerful forces, including health care reform, are sweeping the pharmaceutical market in China, rewriting the rules for both multinational corporations and local companies.